Deep inspirational breast hold (DIBH) for right breast irradiation: Improved sparing of liver and lung tissue.

Breast cancer Deep inspiration breath-hold (DIBH) Gating IMRT Liver Lung Treatment planning

Journal

Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 31 08 2023
revised: 12 01 2024
accepted: 18 01 2024
medline: 2 2 2024
pubmed: 2 2 2024
entrez: 2 2 2024
Statut: epublish

Résumé

To reduce liver and lung dose during right breast irradiation while maintaining optimal dose to the target volume. This dose reduction has the potential to decrease acute side effects and long-term toxicity. 16 patients treated with radiation therapy for localized carcinoma of the right breast were included retrospectively. For the planning CT, each patient was immobilised on an indexed board with the arms placed above the head. CT scans were acquired in free-breathing (FB) as well as with deep inspiration breath hold (DIBH). Both scans were acquired with the same length. Planning target volumes (PTV's) were created with a 5 mm margin from the respective clinical target volumes (CTV's) on both CT datasets. The liver was outlined as scanned. Dose metrics evaluated were as follows: differences in PTV coverage, dose to the liver (max, mean, V90%, V50%, V30%), dose to lung (mean, V20Gy, relative electron density) and dose to heart (Dmax). The p-values were calculated using Wilcoxon signed-rank tests. A p-value was significant when <0.05. Differences in PTV coverage between plans using FB and DIBH were less than 2 %. Maximum liver dose was significantly less using DIBH: 17.5 Gy versus FB: 40.3 Gy (p < 0.001). The volume of the liver receiving 10 % of the dose was significantly less using DIBH with 1.88 cm Radiation of the right breast using DIBH spares liver and lung tissue significantly and thus carries the potential of best practice for right sided breast cancer.

Identifiants

pubmed: 38304241
doi: 10.1016/j.ctro.2024.100731
pii: S2405-6308(24)00008-9
pmc: PMC10832365
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100731

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Thomas Mader (T)

Institute of Radiation Oncology, Cantonal Hospital Graubünden, Chur, Switzerland.

Rachel Pace (R)

Institute of Radiation Oncology, Cantonal Hospital Graubünden, Chur, Switzerland.

Rui T Boucas da Silva (RT)

Institute of Radiation Oncology, Cantonal Hospital Graubünden, Chur, Switzerland.
Department of Radiation Oncology, Cantonal Hospital Winterthur, Winterthur, Switzerland.

Lukas Erwin Johannes Adam (L)

Institute of Radiation Oncology, Cantonal Hospital Graubünden, Chur, Switzerland.

Gabriela Näf (G)

Institute of Radiation Oncology, Cantonal Hospital Graubünden, Chur, Switzerland.

Christopher Charles Winter (C)

Institute of Radiation Oncology, Cantonal Hospital Graubünden, Chur, Switzerland.

Mania Maria Aspradakis (M)

Institute of Radiation Oncology, Cantonal Hospital Graubünden, Chur, Switzerland.
Department of Radiation Oncology, Cantonal Hospital Winterthur, Winterthur, Switzerland.

Marco Radovic (M)

Department of Radiation Oncology, University Hospital Basel, Basel, Switzerland.

Aristotelis Spyridonidis (A)

Institute of Radiation Oncology, Cantonal Hospital Graubünden, Chur, Switzerland.

Stefanie Hayoz (S)

Swiss Group for Clinical Cancer Research (SAKK), Competence Center, Bern, Switzerland.

Brigitta Gertrud Baumert (B)

Institute of Radiation Oncology, Cantonal Hospital Graubünden, Chur, Switzerland.

Classifications MeSH